New Promising Nuclear Medicine Strategy May Benefit Cancer Treatment
Novel nuclear medicine approach can be effective in the treatment of solid tumors in many types of cancer, reports a new study.
A novel nuclear medicine approach is showing great promise for precision treatment of solid tumors in many types of cancer--including lung, breast, pancreas and ovarian in adults and glioma, neuroblastoma, and sarcoma in children. The research was presented at the SNMMI 2018 Annual Meeting, in Philadelphia.
‘Novel nuclear medicine strategy can be effective in the treatment of solid tumors in many types of cancer such as lung, breast, pancreas and ovarian in adults and glioma, neuroblastoma, and sarcoma in children.’
In 2017, researchers from Memorial Sloan Kettering Cancer Center developed a novel approach to pretargeted radioimmunotherapy (DOTA-PRIT) that demonstrated preclinically, complete responses, including cures, in several solid tumor types using the beta-emitting lutetium-177 (177Lu)-DOTA-hapten. In the research presented, the researchers expanded the DOTA-PRIT approach to actinium-225 (225Ac), an alpha-emitting isotope.
"Targeted alpha radiotherapy has shown considerable promise for patients, especially for those with advanced castration-resistance prostate cancer," said Steven M Larson, MD and Sarah M. Cheal, Ph.D., of the Program in Molecular Pharmacology and Department of Radiology at Memorial Sloan Kettering Cancer Center in New York. "By combining DOTA-PRIT with 225Ac-proteus-DOTA hapten, we can potentially target a wide array of cancer types for which we have validated DOTA-PRIT bispecific antibodies (GD2-expressing, HER2-expressing, and GPA33-expressing cancers)."
DOTA-PRIT has a major advantage over other forms of radioimmunotherapy because of its very high ability to deliver radiation to tumors while sparing normal tissues, such as kidney and bone marrow. Larson and Cheal explained, "Creating a targeting alpha radiohapten greatly expands the potential for killing small nests of cells and even single cancer cells, which is likely to be important early in the course of metastatic spread."
A team of researchers synthesized proteus-DOTA, radiolabeled it with 225Ac, and conducted in vitro and in vivo studies of a mouse model with colorectal cancer to determine if pretargeting the tumor with 225c-proteus-DOTA hapten was feasible. A toxicity study was performed in normal tumor-free athymic nude mice with varying dose levels of 225Ac-proteus-DOTA given as a single intravenous injection. Mice were monitored daily for 145 days post-injection and weighed up to twice weekly for evidence of treatment-induced toxicity.
The research team found that their new approach, 225Ac-proteus-DOTA, mimics the behavior of the previously developed approach, 177Lu-DOTA-hapten, with high tumor uptake, minimal accumulation in normal tissue, good whole-body clearance, no acute toxicity and no chronic radiation damage. In addition, the new approach offers greater versatility of treatment for a wide variety of solid tumors and clinical situations.
Larson and Cheal pointed out, "When solid tumors spread beyond surgical control, they are the deadliest tumors for cancer patients. Using the DOTA-PRIT approach, we hope to greatly expand the potential of delivering precision radioimmunotherapy to human solid tumors."
Source: Eurekalert